Leal, formerly known as Trialjectory, has established a predictive patient platform that offers to 1) help cancer patients navigate their treatment journey at all stages of the disease, 2) educate patients and their oncologists about all of their treatment options in a timely manner to remove barriers to care in advance and 3) enable the pharmaceutical industry to identify potential patients that could match to their trials in the future.
A team led by Cedars-Sinai Health Sciences University investigators has created a faster, cheaper way to determine the genes expressed in cancerous tumors. The AI-based tool could make personalized cancer treatment available to more patients.
